Literature DB >> 35373079

Examining the Role of Novel CKD Therapies for the ADPKD Patient.

Dipal M Patel1, Neera K Dahl1.   

Abstract

Entities:  

Keywords:  ADPKD; HIF-PHi; SGLT2i; cystic kidney disease

Mesh：

Year:  2021        PMID： 35373079      PMCID： PMC8791369          DOI： 10.34067/KID.0007422020

Source DB:  PubMed          Journal:  Kidney360        ISSN： 2641-7650


× No keyword cloud information.
  30 in total

1.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.

Authors:  E J Lewis; L G Hunsicker; W R Clarke; T Berl; M A Pohl; J B Lewis; E Ritz; R C Atkins; R Rohde; I Raz
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

2.  Mineralocorticoid Antagonism and Vascular Function in Early Autosomal Dominant Polycystic Kidney Disease: A Randomized Controlled Trial.

Authors:  Kristen L Nowak; Berenice Gitomer; Heather Farmer-Bailey; Wei Wang; Mikaela Malaczewski; Jelena Klawitter; Zhiying You; Diana George; Nayana Patel; Anna Jovanovich; Michel Chonchol
Journal:  Am J Kidney Dis       Date:  2019-02-23       Impact factor: 8.860

Review 3.  SGLT2 inhibition and kidney protection.

Authors:  Josselin Nespoux; Volker Vallon
Journal:  Clin Sci (Lond)       Date:  2018-06-28       Impact factor: 6.124

4.  Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.

Authors:  Christoph Wanner; Silvio E Inzucchi; Bernard Zinman
Journal:  N Engl J Med       Date:  2016-11-03       Impact factor: 91.245

5.  Long-term trajectory of kidney function in autosomal-dominant polycystic kidney disease.

Authors:  Alan S L Yu; Chengli Shen; Douglas P Landsittel; Jared J Grantham; Larry T Cook; Vicente E Torres; Arlene B Chapman; Kyongtae Ty Bae; Michal Mrug; Peter C Harris; Frederic F Rahbari-Oskoui; Tiange Shi; William M Bennett
Journal:  Kidney Int       Date:  2019-03-04       Impact factor: 10.612

6.  Targeting of sodium-glucose cotransporters with phlorizin inhibits polycystic kidney disease progression in Han:SPRD rats.

Authors:  Xueqi Wang; Suhua Zhang; Yang Liu; Daniela Spichtig; Sarika Kapoor; Hermann Koepsell; Nilufar Mohebbi; Stephan Segerer; Andreas L Serra; Daniel Rodriguez; Olivier Devuyst; Changlin Mei; Rudolf P Wüthrich
Journal:  Kidney Int       Date:  2013-05-29       Impact factor: 10.612

7.  Tolvaptan in patients with autosomal dominant polycystic kidney disease.

Authors:  Vicente E Torres; Arlene B Chapman; Olivier Devuyst; Ron T Gansevoort; Jared J Grantham; Eiji Higashihara; Ronald D Perrone; Holly B Krasa; John Ouyang; Frank S Czerwiec
Journal:  N Engl J Med       Date:  2012-11-03       Impact factor: 91.245

8.  Dapagliflozin in Patients with Chronic Kidney Disease.

Authors:  Hiddo J L Heerspink; Bergur V Stefánsson; Ricardo Correa-Rotter; Glenn M Chertow; Tom Greene; Fan-Fan Hou; Johannes F E Mann; John J V McMurray; Magnus Lindberg; Peter Rossing; C David Sjöström; Roberto D Toto; Anna-Maria Langkilde; David C Wheeler
Journal:  N Engl J Med       Date:  2020-09-24       Impact factor: 91.245

Review 9.  The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study.

Authors:  William G Herrington; David Preiss; Richard Haynes; Maximilian von Eynatten; Natalie Staplin; Sibylle J Hauske; Jyothis T George; Jennifer B Green; Martin J Landray; Colin Baigent; Christoph Wanner
Journal:  Clin Kidney J       Date:  2018-10-25

10.  Roxadustat for Treating Anemia in Patients with CKD Not on Dialysis: Results from a Randomized Phase 3 Study.

Authors:  Steven Fishbane; Mohamed A El-Shahawy; Roberto Pecoits-Filho; Bui Pham Van; Mark T Houser; Lars Frison; Dustin J Little; Nicolas J Guzman; Pablo E Pergola
Journal:  J Am Soc Nephrol       Date:  2021-02-10       Impact factor: 10.121
View more
  1 in total

Review 1.  Sodium-glucose cotransporter inhibition in polycystic kidney disease: fact or fiction.

Authors:  Baris Afsar; Rengin Elsurer Afsar; Atalay Demiray; Sevval Altay; Hakan Korkmaz; Abdulmecit Yildiz; Adrian Covic; Alberto Ortiz; Mehmet Kanbay
Journal:  Clin Kidney J       Date:  2022-01-31
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.